Gloria Pharmaceuticals Co., of Beijing, and Cumberland Pharmaceuticals Inc., of Nashville, Tenn., formed a joint R&D initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority-owned by Cumberland and partnered with academic research centers to develop promising biopharmaceutical technologies.